NEWS

News Articles

GeoVax Announces Closing of $10 Million Private Placement

January 21, 2022

GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, announced today the closing of its previously announced private placement for the issuance and sale of 707,484 shares of common stock, 2,360,000 pre-funded warrants to purchase common stock, and accompanying warrants to purchase an aggregate of up to 3,067,484…

Read More

UCB to acquire Zogenix

January 19, 2022

– Transaction broadens and builds upon UCB’s role as a leader in, and our continued commitment to, addressing unmet needs of people living with epilepsy, complementing existing medicines and expanding clinical development pipeline of epilepsy and rare disease therapies – Adds treatment option for specific, vulnerable patient populations with FINTEPLA® (fenfluramine) C-IV oral solution –…

Read More

Trulieve and Morehouse School of Medicine Partner for Cannabis Research and Education

January 18, 2022

Trulieve Cannabis Corp (CSE: TRUL) (OTC: TCNNF) (“Trulieve” or the “Company”), a leading and top-performing cannabis company in the United States, today announced that it has partnered with Morehouse School of Medicine to fund and conduct medical cannabis research and education. Trulieve and the Morehouse School of Medicine have entered into a mutually agreeable collaborative research, education, and development agreement where…

Read More

U.S. FDA approves drugs from AbbVie, Pfizer to treat eczema

January 18, 2022

The U.S. Food and Drug Administration approved drugs from AbbVie Inc (ABBV.N) and Pfizer Inc (PFE.N) for treating eczema, a skin disease, the companies said on Friday. AbbVie’s Rinvoq and Pfizer’s Cibinqo have been approved to treat moderate-to-severe atopic dermatitis, or eczema, in patients who do not respond to previous treatment or when use of other treatments is not…

Read More

Moonlight Therapeutics completes pre-IND meeting with FDA

January 18, 2022

Moonlight Therapeutics Completes Pre-IND Meeting With FDA for MOON101 for Peanut Allergy MOON101 is Moonlight’s lead program for treating peanut allergy using a dermal stamp Moonlight Therapeutics, Inc., a biotechnology company developing targeted treatments for food allergies, announced today it successfully completed a pre-Investigational New Drug Application (pre-IND) meeting with the U.S. Food and Drug…

Read More

GeoVax Announces $10 Million Private Placement

January 14, 2022

ATLANTA, GA, January 14, 2022 — GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, announced today that it has entered into a securities purchase agreement with a single institutional investor to raise approximately $10.0 million through the private placement of 707,484 shares of common stock, 2,360,000 pre-funded…

Read More